46
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Sensory neuropathy in amyotrophic lateral sclerosis: a systematic review

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the degeneration of both upper and lower motoneurons, leading to motor and non-motor symptoms. Recent evidence suggests that ALS is indeed a multisystem disorder, associated with cognitive impairment, dysautonomia, pain and fatigue, excess of secretions, and sensory symptoms. To evaluate whether sensory neuropathy could broaden its spectrum, we systematically reviewed its presence and characteristics in ALS, extracting data on epidemiological, clinical, neurophysiological, neuropathological, and genetic features. Sensory neuropathy can be found in up to 20% of ALS patients, affecting both large and small fibers, although there is a great heterogeneity related to different techniques used for its detection (electromyography vs skin biopsy vs nerve biopsy). Moreover, the association between CIDP-like neuropathy and ALS needs to be better explored, although it could be interpreted as part of the neuroinflammatory process in the latter disease. Sensory neuropathy in ALS may be associated with a spinal onset and might be more frequent in SOD1 patients. Moreover, it seems mutually exclusive with cognitive impairment. No associations with sex and other genetic mutation were observed. All these data in the literature reveal the importance of actively looking for sensory neuropathy in ALS patients, and suggest including sensory neuropathy among ALS non-motor features, as it may explain sensory symptoms frequently reported throughout the course of the disease. Its early identification could help avoid diagnostic delays and improve patients’ treatment and quality of life.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

          The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement, published in 2009, was designed to help systematic reviewers transparently report why the review was done, what the authors did, and what they found. Over the past decade, advances in systematic review methodology and terminology have necessitated an update to the guideline. The PRISMA 2020 statement replaces the 2009 statement and includes new reporting guidance that reflects advances in methods to identify, select, appraise, and synthesise studies. The structure and presentation of the items have been modified to facilitate implementation. In this article, we present the PRISMA 2020 27-item checklist, an expanded checklist that details reporting recommendations for each item, the PRISMA 2020 abstract checklist, and the revised flow diagrams for original and updated reviews.
            • Record: found
            • Abstract: found
            • Article: not found

            Amyotrophic lateral sclerosis

            Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by the degeneration of both upper and lower motor neurons, which leads to muscle weakness and eventual paralysis. Until recently, ALS was classified primarily within the neuromuscular domain, although new imaging and neuropathological data have indicated the involvement of the non-motor neuraxis in disease pathology. In most patients, the mechanisms underlying the development of ALS are poorly understood, although a subset of patients have familial disease and harbour mutations in genes that have various roles in neuronal function. Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria.
              • Record: found
              • Abstract: not found
              • Article: not found
              Is Open Access

              A proposal for new diagnostic criteria for ALS

                Author and article information

                Contributors
                f.pozzi26@campus.unimib.it
                Journal
                J Neurol
                J Neurol
                Journal of Neurology
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0340-5354
                1432-1459
                23 August 2023
                23 August 2023
                2023
                : 270
                : 12
                : 5677-5691
                Affiliations
                [1 ]“Rita Levi Montalcini” Department of Neuroscience, University of Turin, ( https://ror.org/048tbm396) Turin, Italy
                [2 ]Department of Neuromuscular Diseases, Queen Square Institute of Neurology, UCL, ( https://ror.org/048b34d51) London, WC1N 3BG UK
                [3 ]Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, ( https://ror.org/044k9ta02) 90127 Palermo, Italy
                [4 ]GRID grid.7563.7, ISNI 0000 0001 2174 1754, Neuroscience, , University of Milano-Bicocca, ; Milan, Italy
                [5 ]GRID grid.415025.7, ISNI 0000 0004 1756 8604, Neurology Department, , Fondazione IRCCS San Gerardo, ; Monza, Italy
                [6 ]SC Neurologia 1U, Città della Salute e della Scienza di Torino, Turin, Italy
                Author information
                http://orcid.org/0000-0002-3961-6780
                http://orcid.org/0000-0003-2982-9165
                http://orcid.org/0000-0002-9995-8133
                http://orcid.org/0000-0001-9805-1655
                Article
                11954
                10.1007/s00415-023-11954-1
                10632209
                37610446
                c53f52ac-0bf4-4992-b315-fed30a31d559
                © The Author(s) 2023

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 June 2023
                : 14 August 2023
                : 17 August 2023
                Funding
                Funded by: Università degli Studi di Milano - Bicocca
                Categories
                Review
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2023

                Neurology
                amyotrophic lateral sclerosis,sensory neuropathy,systematic review,neurodegeneration,non-motor symptoms

                Comments

                Comment on this article

                Related Documents Log